NTE Events Archive
» Go to news mainFair Pricing of "Old" Orphan Drugs: Considerations for Canada's Orphan Drug Policy
Posted by NTE on
April 7, 2015
in
In Print
Eve Roberts, Matthew Herder and Aiden Hollis. Fair pricing of "old" orphan drugs: Considerations for Canada's orphan drug policy. CMAJ. 187(6): pp.422-425 (subscription only)
CMAJ podcast review of the issue (starting at 6:25)
Recent News
- On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
- Matthew Herder Resigns from Patented Medicine Prices Review Board
- Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
- Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
- Podcast or Perish: Episode 040: Françoise Baylis
- Bioethicist Françoise Baylis asks why humans think 'they can just take everything'
- Killam Prize winners discuss research in Canada
- World‑renowned Dalhousie bioethicist and battery pioneer win prestigious Killam Prize